Dual GIP/GLP-1 Receptor Agonist
An injectable treatment acting on two gut-hormone pathways to reduce appetite and improve blood sugar control. Prescription only, after medical assessment.
Plain English
Patient-Friendly Explanation
A dual GIP/GLP-1 receptor agonist is a newer type of weight-loss medication that acts on two natural gut hormones at once. Activating both pathways produces stronger appetite control and greater weight loss than targeting one alone.
Medical
Clinical Definition
Dual GIP/GLP-1 receptor agonists are a newer class of incretin-based therapy that simultaneously activates receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). In registration trials of the first approved dual agonist, mean weight reductions of approximately 15–21% at 72 weeks were reported, compared with about 3% in the placebo group, alongside significant HbA1c lowering. The GIP component is believed to contribute metabolic and body-composition benefits beyond GLP-1 alone, though the precise mechanisms remain under investigation. Gastrointestinal side effects are similar in nature to GLP-1 receptor agonists and are mitigated by gradual dose titration.
Key Insight
Why It Matters
This is the newest wave of weight-loss science — treating the gut's own hormone system more completely. When appropriate, our doctors can discuss whether dual-agonist therapy fits your medical profile and goals.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: August 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
